{"entity":{"type":"insider","cik":"0001902368","url":"/insider/0001902368","json_url":"/insider/0001902368.json","name":"Inrig Jula","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":24,"n_filings":15,"first":"2023-01-06","last":"2026-05-06","span_basis":"filed_date"},"name_variants":[{"name":"Inrig Jula","source":"filing","n_filings":15,"first_seen":"2023-01-06","last_seen":"2026-05-06"}],"transactions":[{"id":5806766,"accession":"0001902368-26-000006","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001902368-26-000006","line_url":"/filing/0001902368-26-000006#line-5","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":311.0,"shares_display":"311","price_per_share":43.95,"price_display":"43.95","price_state":"stated","total_value":13668.45,"total_display":"13,668.45","total_whole":"13,668","shares_owned_after":113238.0,"shares_owned_after_display":"113,238","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-06","filed_date":"2026-05-06","scope":"insider"},{"id":5806764,"accession":"0001902368-26-000006","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001902368-26-000006","line_url":"/filing/0001902368-26-000006#line-4","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2174.0,"shares_display":"2,174","price_per_share":46.65,"price_display":"46.65","price_state":"stated","total_value":101417.1,"total_display":"101,417.10","total_whole":"101,417","shares_owned_after":113549.0,"shares_owned_after_display":"113,549","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-05","filed_date":"2026-05-06","scope":"insider"},{"id":5806762,"accession":"0001902368-26-000006","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001902368-26-000006","line_url":"/filing/0001902368-26-000006#line-3","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":45.0,"price_display":"45.00","price_state":"stated","total_value":900000.0,"total_display":"900,000.00","total_whole":"900,000","shares_owned_after":111473.0,"shares_owned_after_display":"111,473","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-04","filed_date":"2026-05-06","scope":"insider"},{"id":5971466,"accession":"0001902368-26-000005","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001902368-26-000005","line_url":"/filing/0001902368-26-000005#line-3","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1018.0,"shares_display":"1,018","price_per_share":42.61,"price_display":"42.61","price_state":"stated","total_value":43376.98,"total_display":"43,376.98","total_whole":"43,377","shares_owned_after":111473.0,"shares_owned_after_display":"111,473","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-15","filed_date":"2026-04-15","scope":"insider"},{"id":5971463,"accession":"0001902368-26-000005","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001902368-26-000005","line_url":"/filing/0001902368-26-000005#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7215.0,"shares_display":"7,215","price_per_share":41.9288,"price_display":"41.93","price_state":"stated","total_value":302516.292,"total_display":"302,516.29","total_whole":"302,516","shares_owned_after":112491.0,"shares_owned_after_display":"112,491","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-14","filed_date":"2026-04-15","scope":"insider"},{"id":6181705,"accession":"0001902368-26-000004","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001902368-26-000004","line_url":"/filing/0001902368-26-000004","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1779.0,"shares_display":"1,779","price_per_share":32.206503653738054,"price_display":"32.21","price_state":"stated","total_value":57295.37,"total_display":"57,295.37","total_whole":"57,295","shares_owned_after":105938.0,"shares_owned_after_display":"105,938","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-04","filed_date":"2026-02-05","scope":"insider","n_lines":2},{"id":5753962,"accession":"0001902368-26-000003","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001902368-26-000003","line_url":"/filing/0001902368-26-000003#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6956.0,"shares_display":"6,956","price_per_share":32.12,"price_display":"32.12","price_state":"stated","total_value":223426.72,"total_display":"223,426.72","total_whole":"223,427","shares_owned_after":107485.0,"shares_owned_after_display":"107,485","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-03","filed_date":"2026-02-03","scope":"insider"},{"id":5912517,"accession":"0001902368-26-000002","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001902368-26-000002","line_url":"/filing/0001902368-26-000002#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":445.0,"shares_display":"445","price_per_share":37.75,"price_display":"37.75","price_state":"stated","total_value":16798.75,"total_display":"16,798.75","total_whole":"16,799","shares_owned_after":86311.0,"shares_owned_after_display":"86,311","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-06","filed_date":"2026-01-07","scope":"insider"},{"id":5912515,"accession":"0001902368-26-000002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001902368-26-000002","line_url":"/filing/0001902368-26-000002#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2031.0,"shares_display":"2,031","price_per_share":40.18,"price_display":"40.18","price_state":"stated","total_value":81605.58,"total_display":"81,605.58","total_whole":"81,606","shares_owned_after":86756.0,"shares_owned_after_display":"86,756","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-05","filed_date":"2026-01-07","scope":"insider"},{"id":5135211,"accession":"0001902368-25-000005","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001902368-25-000005","line_url":"/filing/0001902368-25-000005#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":42.0003,"price_display":"42.00","price_state":"stated","total_value":630004.5,"total_display":"630,004.50","total_whole":"630,005","shares_owned_after":88787.0,"shares_owned_after_display":"88,787","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-24","filed_date":"2025-12-29","scope":"insider"},{"id":4211700,"accession":"0001415889-25-019108","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-019108","line_url":"/filing/0001415889-25-019108#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":815.0,"shares_display":"815","price_per_share":14.65,"price_display":"14.65","price_state":"stated","total_value":11939.75,"total_display":"11,939.75","total_whole":"11,940","shares_owned_after":88787.0,"shares_owned_after_display":"88,787","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-01","filed_date":"2025-07-02","scope":"insider"},{"id":5122297,"accession":"0001415889-25-003819","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-003819","line_url":"/filing/0001415889-25-003819#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2568.0,"shares_display":"2,568","price_per_share":23.5302,"price_display":"23.53","price_state":"stated","total_value":60425.5536,"total_display":"60,425.55","total_whole":"60,426","shares_owned_after":89602.0,"shares_owned_after_display":"89,602","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-12","filed_date":"2025-02-12","scope":"insider"},{"id":4769282,"accession":"0001415889-25-003064","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-25-003064","line_url":"/filing/0001415889-25-003064#line-3","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1066.0,"shares_display":"1,066","price_per_share":20.11,"price_display":"20.11","price_state":"stated","total_value":21437.26,"total_display":"21,437.26","total_whole":"21,437","shares_owned_after":84170.0,"shares_owned_after_display":"84,170","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-04","filed_date":"2025-02-04","scope":"insider"},{"id":4769277,"accession":"0001415889-25-003064","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-003064","line_url":"/filing/0001415889-25-003064#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4207.0,"shares_display":"4,207","price_per_share":20.12,"price_display":"20.12","price_state":"stated","total_value":84644.84,"total_display":"84,644.84","total_whole":"84,645","shares_owned_after":85236.0,"shares_owned_after_display":"85,236","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-03","filed_date":"2025-02-04","scope":"insider"},{"id":4499908,"accession":"0001415889-25-000899","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-000899","line_url":"/filing/0001415889-25-000899#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":440.0,"shares_display":"440","price_per_share":18.76,"price_display":"18.76","price_state":"stated","total_value":8254.4,"total_display":"8,254.40","total_whole":"8,254","shares_owned_after":59443.0,"shares_owned_after_display":"59,443","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-06","filed_date":"2025-01-06","scope":"insider"},{"id":4499906,"accession":"0001415889-25-000899","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-000899","line_url":"/filing/0001415889-25-000899#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2066.0,"shares_display":"2,066","price_per_share":19.1,"price_display":"19.10","price_state":"stated","total_value":39460.6,"total_display":"39,460.60","total_whole":"39,461","shares_owned_after":59883.0,"shares_owned_after_display":"59,883","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-03","filed_date":"2025-01-06","scope":"insider"},{"id":2279620,"accession":"0001415889-24-023128","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-023128","line_url":"/filing/0001415889-24-023128#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":684.0,"shares_display":"684","price_per_share":12.98,"price_display":"12.98","price_state":"stated","total_value":8878.32,"total_display":"8,878.32","total_whole":"8,878","shares_owned_after":61949.0,"shares_owned_after_display":"61,949","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-10","filed_date":"2024-09-10","scope":"insider"},{"id":3086822,"accession":"0001415889-24-023093","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-023093","line_url":"/filing/0001415889-24-023093#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2191.0,"shares_display":"2,191","price_per_share":11.52,"price_display":"11.52","price_state":"stated","total_value":25240.32,"total_display":"25,240.32","total_whole":"25,240","shares_owned_after":62633.0,"shares_owned_after_display":"62,633","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-09","filed_date":"2024-09-09","scope":"insider"},{"id":3140603,"accession":"0001415889-24-002281","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-002281","line_url":"/filing/0001415889-24-002281#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (CHIEF MEDICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF MEDICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF MEDICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2174.0,"shares_display":"2,174","price_per_share":8.5311,"price_display":"8.53","price_state":"stated","total_value":18546.6114,"total_display":"18,546.61","total_whole":"18,547","shares_owned_after":58074.0,"shares_owned_after_display":"58,074","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-01","filed_date":"2024-02-02","scope":"insider"},{"id":3243103,"accession":"0001209191-24-001005","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-24-001005","line_url":"/filing/0001209191-24-001005#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":440.0,"shares_display":"440","price_per_share":9.17,"price_display":"9.17","price_state":"stated","total_value":4034.8,"total_display":"4,034.80","total_whole":"4,035","shares_owned_after":35248.0,"shares_owned_after_display":"35,248","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-04","filed_date":"2024-01-05","scope":"insider"},{"id":3243102,"accession":"0001209191-24-001005","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-24-001005","line_url":"/filing/0001209191-24-001005#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2069.0,"shares_display":"2,069","price_per_share":9.4794,"price_display":"9.48","price_state":"stated","total_value":19612.8786,"total_display":"19,612.88","total_whole":"19,613","shares_owned_after":35688.0,"shares_owned_after_display":"35,688","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-03","filed_date":"2024-01-05","scope":"insider"},{"id":7829496,"accession":"0001209191-23-002325","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-002325","line_url":"/filing/0001209191-23-002325#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":442.0,"shares_display":"442","price_per_share":20.75,"price_display":"20.75","price_state":"stated","total_value":9171.5,"total_display":"9,171.50","total_whole":"9,172","shares_owned_after":17507.0,"shares_owned_after_display":"17,507","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-05","filed_date":"2023-01-06","scope":"insider"},{"id":7829490,"accession":"0001209191-23-002325","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-002325","line_url":"/filing/0001209191-23-002325#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001902368","owner_name":"Inrig Jula","owner_display_name":"Inrig Jula","owner_url":"/insider/0001902368","role":"Officer (Chief Medical Officer)","role_mark":"O","role_mark_label":"Officer (Chief Medical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Medical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2051.0,"shares_display":"2,051","price_per_share":20.75,"price_display":"20.75","price_state":"stated","total_value":42558.25,"total_display":"42,558.25","total_whole":"42,558","shares_owned_after":17949.0,"shares_owned_after_display":"17,949","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-04","filed_date":"2023-01-06","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":24,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":24,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":24},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001438533","name":"Travere Therapeutics, Inc.","url":"/issuer/0001438533","role":"Officer (CHIEF MEDICAL OFFICER)","n_filings":15,"first_seen":"2023-01-06","last_seen":"2026-05-06"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001902368","retrieved_at":"2026-08-25T08:26:12+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}